These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23675603)

  • 1. [Compensatory mechanisms in multiple sclerosis(review)].
    Peresedova AV; Zavalishin IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):17-22. PubMed ID: 23675603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic aspects of multiple sclerosis.
    Boppana S; Huang H; Ito K; Dhib-Jalbut S
    Mt Sinai J Med; 2011; 78(2):207-20. PubMed ID: 21425265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of a meeting to discuss neurodegeneration, neuroprotection and repair, and the interrelated issues of glial cells and myelin in multiple sclerosis. May 24, 2006. Geneva, Switzerland.
    Neurology; 2007 May; 68(22 Suppl 3):S2-96. PubMed ID: 17548564
    [No Abstract]   [Full Text] [Related]  

  • 4. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R; Arnon R
    Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-mediated neurodegeneration and neuroprotection in MS.
    Giuliani F; Yong VW
    Int MS J; 2003 Dec; 10(4):122-30. PubMed ID: 14977489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regenerative capacity in multiple sclerosis].
    Lubetzki C
    Bull Acad Natl Med; 2008 Mar; 192(3):495-504; discussion 505-6. PubMed ID: 18819695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
    Zamvil SS; Steinman L
    Neuron; 2003 Jun; 38(5):685-8. PubMed ID: 12797954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology?
    Desmazières A; Sol-Foulon N; Lubetzki C
    Mult Scler; 2012 Feb; 18(2):133-7. PubMed ID: 22217583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological aspects of axon injury in multiple sclerosis.
    Howe CL
    Curr Top Microbiol Immunol; 2008; 318():93-131. PubMed ID: 18219816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axonal protection in multiple sclerosis--a particular need during remyelination?
    Smith KJ
    Brain; 2006 Dec; 129(Pt 12):3147-9. PubMed ID: 17132643
    [No Abstract]   [Full Text] [Related]  

  • 12. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches.
    Olsen JA; Akirav EM
    J Neurosci Res; 2015 May; 93(5):687-96. PubMed ID: 25287108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression.
    Zeydan B; Rodriguez M; Kantarci OH
    Adv Exp Med Biol; 2017; 958():161-170. PubMed ID: 28093713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural products: Potential therapeutic agents in multiple sclerosis.
    Yu S; Liu M; Hu K
    Int Immunopharmacol; 2019 Feb; 67():87-97. PubMed ID: 30537635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies?
    Stys PK
    Ann Neurol; 2004 May; 55(5):601-3. PubMed ID: 15122698
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting remyelination in multiple sclerosis: current drugs and future prospects.
    Kremer D; Küry P; Dutta R
    Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axonal damage in multiple sclerosis: a complex issue in a complex disease.
    Grigoriadis N; Ben-Hur T; Karussis D; Milonas I
    Clin Neurol Neurosurg; 2004 Jun; 106(3):211-7. PubMed ID: 15177770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination.
    Seiwa C; Yamamoto M; Tanaka K; Fukutake M; Ueki T; Takeda S; Sakai R; Ishige A; Watanabe K; Akita M; Yagi T; Tanaka K; Asou H
    J Neurosci Res; 2007 Apr; 85(5):954-66. PubMed ID: 17290413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.